➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Harvard Business School
AstraZeneca
Moodys
McKinsey

Last Updated: September 24, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LUCINACTANT

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Lucinactant

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004500 ↗ Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration Syndrome Terminated Windtree Therapeutics Phase 3 2000-03-01 OBJECTIVES: Evaluate the safety and efficacy of lucinactant administered by bronchoalveolar lavage (BAL) in the treatment of meconium aspiration syndrome (MAS) in newborn infants.
NCT00215540 ↗ SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants. Terminated Windtree Therapeutics Phase 2 2005-02-01 SURFAXIN® (lucinactant) treatment will be examined in very low birth weight infants to prevent development of chronic lung disease, commonly known as bronchopulmonary dysplasia (BPD), in premature infants who have required continued intubation and received surfactants for the prevention or treatment of respiratory distress syndrome (RDS).
NCT00215553 ↗ KL₄Surfactant Treatment in Patients With ARDS Terminated Windtree Therapeutics Phase 2 2001-05-01 Lung wash with KL₄Surfactant of individual lung segments using a bronchoscope compared to usual care alone consisting primarily of assisted (mechanical) ventilation in patients with acute respiratory distress syndrome(ARDS).
NCT00578734 ↗ Lucinactant for Treatment of Acute Hypoxemic Respiratory Failure in Children up to Two Years Old Completed Windtree Therapeutics Phase 2 2007-06-01 Treatment with lucinactant, a peptide-containing synthetic lung surfactant, will be evaluated in young children with acute respiratory failure who require mechanical ventilation (life support), to determine if it is safe and if treatment with lucinactant will reduce the number of days a child needs mechanical ventilation (life support).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lucinactant

Condition Name

Condition Name for Lucinactant
Intervention Trials
Respiratory Distress Syndrome 3
Cystic Fibrosis 1
COVID-19 1
Bronchopulmonary Dysplasia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Lucinactant
Intervention Trials
Respiratory Distress Syndrome, Newborn 6
Respiratory Distress Syndrome, Adult 6
Syndrome 3
Acute Lung Injury 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lucinactant

Trials by Country

Trials by Country for Lucinactant
Location Trials
United States 25
Poland 12
Chile 4
Canada 3
Netherlands 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Lucinactant
Location Trials
Pennsylvania 4
California 3
Oregon 2
New York 2
Nebraska 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lucinactant

Clinical Trial Phase

Clinical Trial Phase for Lucinactant
Clinical Trial Phase Trials
Phase 3 1
Phase 2 7
Phase 1/Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Lucinactant
Clinical Trial Phase Trials
Terminated 4
Recruiting 2
Completed 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lucinactant

Sponsor Name

Sponsor Name for Lucinactant
Sponsor Trials
Windtree Therapeutics 9
University of North Carolina, Chapel Hill 1
Cystic Fibrosis Foundation Therapeutics 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Lucinactant
Sponsor Trials
Industry 9
Other 2
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Medtronic
Baxter
McKinsey
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.